3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
97
Myelodysplastic Syndromes
20
Leukemia, Myelomonocytic, Chronic
10
Recurrence
8
Leukemia
8
Neoplasm, Residual
6
Hematologic Neoplasms
6
Myeloproliferative Disorders
5
Lymphoma, T-Cell, Peripheral
5
Leukemia, Biphenotypic, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Monocytic, Acute
3
Anemia, Refractory, with Excess of Blasts
3
Myeloid Malignancy
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
GATA2 Deficiency
2
Breast Neoplasms
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Myeloid
1
Pyloric Stenosis, Hypertrophic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Interventions
pembrolizumab
26
Cisplatin
17
Radiotherapy
13
Carboplatin
13
Blood Specimen Collection
10
Cetuximab
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
5
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
Surgical Procedures, Operative
3
Radiotherapy, Intensity-Modulated
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
fludarabine
2
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Tablets
2
Standard of Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
Azacitidine
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled